# Nephropathy In Type 2 Diabetes and Cardio-renal Events

> **NCT00535925** · PHASE4 · COMPLETED · sponsor: **University of Campania Luigi Vanvitelli** · enrollment: 850 (actual)

## Conditions studied

- Diabetic Nephropathy

## Interventions

- **DRUG:** SoC therapy
- **DRUG:** irbesartan
- **DRUG:** ramipril
- **DRUG:** hydrochlorothiazide
- **DRUG:** furosemide
- **DRUG:** amlodipine
- **DRUG:** atenolol
- **DRUG:** doxazosin
- **DRUG:** clonidine
- **DRUG:** insulin
- **DRUG:** simvastatin
- **DRUG:** fibrate
- **DRUG:** erythropoietin
- **DRUG:** aspirin

## Key facts

- **NCT ID:** NCT00535925
- **Lead sponsor:** University of Campania Luigi Vanvitelli
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2011-12
- **Final completion:** 2019-05
- **Target enrollment:** 850 (ACTUAL)
- **Last updated:** 2020-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00535925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00535925, "Nephropathy In Type 2 Diabetes and Cardio-renal Events". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00535925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*